Your session is about to expire
← Back to Search
TIL Therapy for Cancer
Study Summary
This trial will test how well LN-145 or LN-145-S1 work in treating patients with ovarian cancer, triple negative breast cancer, anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment or that has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have severe ongoing side effects from previous treatments, active hepatitis, heart issues, or a history of certain cell therapies.I had severe diarrhea or colitis from past immunotherapy but have been symptom-free for 6 months or had a normal colonoscopy.I can have a piece of my tumor removed for testing, separate from the main cancer area.I stopped any cancer treatments 28 days before enrolling for TIL therapy, except with PI approval for palliative care.I do not have any severe ongoing illnesses that are not under control.My heart test (stress echo) results were normal, or I had an alternative heart check approved by a cardiologist.I am between 18 and 70 years old.Your recent heart test should not show signs of heart problems, and a specific measurement of your heart's electrical activity should be within a certain range.You can breathe out and take deep breaths normally, without any significant problems.Your blood and other body chemistry levels need to be within certain ranges.Different types of cancer have their own specific rules for who can participate in the study.I am fully active or restricted in physically strenuous activity but can do light work.Women who could become pregnant must have a negative pregnancy test within 7 days before joining the study.I do not have HIV.
- Group 1: ICI Ovarian Cancer, Sarcomas, Triple Negative Breast Cancer (LN-145-S1, nivolumab)
- Group 2: Thyroid Cohort (LN-145)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have previous studies analyzed the efficacy of Autologous Tumor Infiltrating Lymphocytes LN-145?
"Currently, there are 1,647 separate investigations into autologous tumor infiltrating lymphocytes LN-145 being conducted; 246 of these clinical trials have reached phase 3. Primarily concentrated in Philadelphia, Pennsylvania but running globally on 70,461 sites, the scope of this research is truly expansive."
To what extent has recruitment for this medical experiment been successful?
"Affirmative, the information on clinicaltrials.gov attests that this experiment is actively recruiting subjects. This trial was initially posted in April 2018 and last updated in August of 2022; 95 individuals are being sought from 1 research site."
Are there specific qualifications that must be met for participation in this medical study?
"This clinical trial seeks 95 volunteers between the ages of 16 and 70, who have giant cell tumor of bone. Moreover, to qualify for inclusion in this study, participants must be 18-70 years old (subjects aged 16-17 may join the osteosarcoma cohort), willing to provide informed consent or parental/legal guardian permission if under 18, have an ECOG performance status 0 or 1; a biopsy site that can produce TIL separate from target lesions amenable to response assessment; discontinued any prior targeted therapies 28 days before enrollment; ANC ≥ 1000mm^3 within 7 days pre-enrollment; hemoglobin ≥"
What maladies has Autologous Tumor Infiltrating Lymphocytes LN-145 been employed to help alleviate?
"Autologous Tumor Infiltrating Lymphocytes LN-145 is a viable treatment for multiple sclerosis and various other diseases like leukemia, myelocytic neoplasms, unresectable melanoma."
Are there vacancies available for participant involvement in this medical trial?
"Affirmative. The information hosted on clinicaltrials.gov shows that this medical research, which was first announced in April 2018, is still recruiting participants to its single site for the total of 95 patients."
Is this study open to adults beyond the age of twenty-five?
"This medical study is looking for individuals aged between 16 and 70 years old."
Has the Food and Drug Administration endorsed Autologous Tumor Infiltrating Lymphocytes LN-145?
"Although Autologous Tumor Infiltrating Lymphocytes LN-145 has yet to be proven efficacious, existing safety data allows our team at Power to rate its safety a 2 on the scale from 1 to 3."
Share this study with friends
Copy Link
Messenger